2,574 reports of this reaction
1.2% of all CLOZAPINE reports
#20 most reported adverse reaction
LEUKOPENIA is the #20 most commonly reported adverse reaction for CLOZAPINE, manufactured by HLS Therapeutics (USA), Inc.. There are 2,574 FDA adverse event reports linking CLOZAPINE to LEUKOPENIA. This represents approximately 1.2% of all 207,229 adverse event reports for this drug.
Patients taking CLOZAPINE who experience leukopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LEUKOPENIA is a less commonly reported adverse event for CLOZAPINE, but still significant enough to appear in the safety profile.
In addition to leukopenia, the following adverse reactions have been reported for CLOZAPINE:
The following drugs have also been linked to leukopenia in FDA adverse event reports:
LEUKOPENIA has been reported as an adverse event in 2,574 FDA reports for CLOZAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
LEUKOPENIA accounts for approximately 1.2% of all adverse event reports for CLOZAPINE, making it a notable side effect.
If you experience leukopenia while taking CLOZAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.